 |
|
|
| |
Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year After Switching to Tenofovir Alafenamide From Tenofovir Disoproxil Fumarate
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2018 SF
References: 1. Babusis D, et al. Mol Pharmaceutics 2013;10:459-66; 2. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 3. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 4. Agarwal K, et al. J Hepatol 2015;62:533-40; 5. Sax P, et al. Lancet 2015;385:2606-15; 6. Agarwal K, et al. J Hepatol 2018;68:672-81; 7. Pan C, et al. AASLD 2017, poster 904.
Acknowledgments: We extend our thanks to the patients, their families, and all participating investigators. These studies were funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
